Skip to content
DataLookout
Menu

KB12NCT07941674

Persistent Vitamin B12 Hypervitaminemia: Identification of Biomarkers for the Early Detection of Solid Cancers

StatusNot Yet Recruiting
PhaseNot applicable
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Between-group differences in vitamin B12-related biomarker concentrations
Timeframe: At inclusion (baseline blood sample)

Secondary (7)

Area under the receiver operating characteristic curve (AUC) for solid cancer detection
Cutoff values of vitamin B12-related biomarkers (Optimal diagnostic)
Sensitivity
specificity
positive predictive value of vitamin B12-related biomarkers
Show 2 moreShow less
negative predictive value of vitamin B12-related biomarkers
Association between vitamin B12-related biomarker concentrations and certain tumor characteristics

Arms and interventions

Persistent elevated B12Experimental

All participants with persistent hypercobalaminemia undergo the same study-specific blood sampling procedure for the measurement of vitamin B12-related biomarkers. Participants are classified into two predefined subgroups according to the underlying cause of hypercobalaminemia: solid cancer (CANCER group) or other identified causes (OTHER CAUSES group). No treatment or diagnostic procedure is assigned differently between the two subgroups.

Diagnostic tests: Blood-Based Vitamin B12 Biomarker Panel

Sites

3 sites in 1 country